30 Ağustos 2021 Dergi makalesi Açık Erişim

Mehmet; Gökhan; Pamir

DataCite XML

<?xml version='1.0' encoding='utf-8'?>
<resource xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://datacite.org/schema/kernel-4" xsi:schemaLocation="http://datacite.org/schema/kernel-4 http://schema.datacite.org/meta/kernel-4.1/metadata.xsd">
  <identifier identifierType="URL">https://aperta.ulakbim.gov.tr/record/227983</identifier>
  <creators>
    <creator>
      <creatorName>Mehmet</creatorName>
      <nameIdentifier nameIdentifierScheme="ORCID" schemeURI="http://orcid.org/">0000-0003-1710-7018</nameIdentifier>
      <affiliation>SOY</affiliation>
    </creator>
    <creator>
      <creatorName>Gökhan</creatorName>
      <nameIdentifier nameIdentifierScheme="ORCID" schemeURI="http://orcid.org/">0000-0001-7289-1816</nameIdentifier>
      <affiliation>KESER</affiliation>
    </creator>
    <creator>
      <creatorName>Pamir</creatorName>
      <nameIdentifier nameIdentifierScheme="ORCID" schemeURI="http://orcid.org/">0000-0002-6393-7461</nameIdentifier>
      <affiliation>ATAGÜNDÜZ</affiliation>
    </creator>
  </creators>
  <titles>
    <title>Pathogenesis And Treatment Of Cytokine Storm In Covid-19</title>
  </titles>
  <publisher>Aperta</publisher>
  <publicationYear>2021</publicationYear>
  <subjects>
    <subject>COVID-19</subject>
    <subject>SARS-CoV-2</subject>
    <subject>cytokine storm</subject>
    <subject>acute respiratory distress syndrome</subject>
    <subject>tocilizumab</subject>
    <subject>anakinra</subject>
  </subjects>
  <dates>
    <date dateType="Issued">2021-08-30</date>
  </dates>
  <resourceType resourceTypeGeneral="Text">Journal article</resourceType>
  <alternateIdentifiers>
    <alternateIdentifier alternateIdentifierType="url">https://aperta.ulakbim.gov.tr/record/227983</alternateIdentifier>
  </alternateIdentifiers>
  <relatedIdentifiers>
    <relatedIdentifier relatedIdentifierType="DOI" relationType="IsIdenticalTo">10.3906/biy-2105-37</relatedIdentifier>
  </relatedIdentifiers>
  <rightsList>
    <rights rightsURI="http://www.opendefinition.org/licenses/cc-by-sa">Creative Commons Attribution Share-Alike</rights>
    <rights rightsURI="info:eu-repo/semantics/openAccess">Open Access</rights>
  </rightsList>
  <descriptions>
    <description descriptionType="Abstract">&lt;p&gt;COVID-19 is a viral infection caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that killed a large&amp;nbsp;number of patients around the world. A hyperinflammatory state resulting in a cytokine storm and adult respiratory distress syndrome&amp;nbsp;seems to be the major cause of the death. Many mechanisms have been suggested in the pathogenesis of COVID-19 associated cytokine&amp;nbsp;storm (COVID-CS). Insufficient viral clearance and persistence of a strong cytokine response despite inadequate antiviral immunity&amp;nbsp;seem to be the main mechanisms underlying the pathogenesis. The diagnosis of COVID-19 is based on relatively constant clinical&amp;nbsp;symptoms, clinical findings, laboratory tests, and imaging techniques, while the diagnosis of COVID-CS is a rather dynamic process,&amp;nbsp;based on evolving or newly emerging findings during the clinical course. Management of COVID-19 consists of using antiviral agents&amp;nbsp;to inhibit SARS-CoV-2 replication and treating potential complications including the cytokine storm together with general supportive&amp;nbsp;measures. COVID-CS may be treated using appropriate immunosuppressive and immunomodulatory drugs that reduce the level of&amp;nbsp;inappropriate systemic inflammation, which has the potential to cause organ damage. Currently corticosteroids, IL-6 blockers, or IL-1&amp;nbsp;blockers are most widely used for treating COVID-CS.&lt;/p&gt;</description>
  </descriptions>
</resource>